No New Trial In Pennsylvania Risperdal Breast Growth Trial; Delay Damages Added

(January 29, 2016, 9:27 AM EST) -- PHILADELPHIA — A Pennsylvania state court judge on Jan. 5 denied a Risperdal plaintiff’s motion for a new trial but granted his motion for delay damages of $35,106, bringing to $535,106 the plaintiff’s recovery against Janssen Pharmaceuticals Inc. (Timothy Stange v. Janssen Pharmaceuticals, Inc., et al., No. 130401984, Pa. Comm. Pls., Philadelphia Co.).

On Dec. 11, a jury in the Philadelphia Common Pleas Court found that Janssen and parent company Johnson & Johnson failed to warn Timothy Stange’s physician about the risk of gynecomastia (enlarged male...
To view the full article, register now.